| Domain | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | |
| Review | Confidence in reviews | ||||||||||||||||
| Ashford et al 201630 | N/A | N/A | N/A | Moderate | |||||||||||||
| Bayrampour et al 201931 | Critically low | ||||||||||||||||
| Callanan et al 202232 | N/A | N/A | N/A | High | |||||||||||||
| Desai et al 202133 | Moderate | ||||||||||||||||
| Dhillon et al 201734 | High | ||||||||||||||||
| Domínguez-Solís et al 202135 | N/A | N/A | N/A | High | |||||||||||||
| Evans et al 201836 | Moderate | ||||||||||||||||
| Evans et al 202053 | N/A | N/A | High | ||||||||||||||
| Evans et al 202237 | Moderate | ||||||||||||||||
| Hall et al 201638 | N/A | N/A | High | ||||||||||||||
| Hall et al 202039 | High | ||||||||||||||||
| HTA report 202140 | Moderate | ||||||||||||||||
| Lau et al 201741 | Moderate | ||||||||||||||||
| Lau et al 202142 | High | ||||||||||||||||
| Lever-Taylor et al 201643 | Low | ||||||||||||||||
| Loughnan et al 201944 | High | ||||||||||||||||
| Maguire et al 201845 | Low | ||||||||||||||||
| Marc et al 201150 | N/A | N/A | High | ||||||||||||||
| Matvienko-Sikar et al 201646 | N/A | N/A | Low | ||||||||||||||
| Matvienko-Sikar et al 202147 | N/A | N/A | N/A | Low | |||||||||||||
| Mueller and Grunwald 202151 | N/A | N/A | N/A | Low | |||||||||||||
| Sánchez-Polán et al 202152 | Low | ||||||||||||||||
| Shi et al 201748 | N/A | N/A | Critically low | ||||||||||||||
| Yan et al 202249 | Moderate |
Domains: 1. research questions and inclusion criteria include the components of PICO? 2. explicit statement that the review methods were established prior to the conduct of the review and justify significant deviations from the protocol 3. explain their selection of the study designs for inclusion 4. use of a comprehensive literature search strategy 5. study selection in duplicate 6. data extraction in duplicate 7. provided list of excluded studies and justification 8. included studies described in adequate detail? 9. satisfactory technique for assessing the risk of bias (RoB) 10. sources of funding for the studies 11. If meta-analysis was performed: appropriate methods for statistical combination of results 12. If meta-analysis was performed: assess the potential impact of RoB in individual studies 13. account for RoB in individual studies when interpreting/ discussing the results of the review? 14. explanation for, and discussion of, any heterogeneity observed 15. If they performed quantitative synthesis: publication bias (small study bias) and discuss its impact 16. report any potential sources of conflict of interest, including funding received
Code for AMSTAR 2 tool: Critical domain = BLUE. Yes = GREEN. Partial yes = YELLOW. No = RED. Not applicable = WHITE.